Merck & Co Inc
NYSE:MRK 1:46:44 PM EDT
Products
FDA Approves Updated Indication For Merck’S Keytruda (Pembrolizumab) For Treatment Of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
Published: 08/31/2021 20:15 GMT
Merck & Co Inc (MRK) - FDA Approves Updated Indication for Merck’s Keytruda® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (bladder Cancer).
FDA Approves Updated Indication for Merck’s Keytruda® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (bladder Cancer).
Merck - Keytruda Approved for Treatment of Patients With Urothelial Carcinoma Who Are Not Eligible for Any Platinum-containing Chemotherapy.
FDA Approves Updated Indication for Merck’s Keytruda® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (bladder Cancer).
Merck - Keytruda Approved for Treatment of Patients With Urothelial Carcinoma Who Are Not Eligible for Any Platinum-containing Chemotherapy.